240 related articles for article (PubMed ID: 35114057)
21. [Organ preservation for rectal cancer: What are the arguments in favor of radiotherapy?].
Larrouy A; Giraud N; Huguet F; Vendrely V
Cancer Radiother; 2022 Oct; 26(6-7):766-770. PubMed ID: 35995720
[TBL] [Abstract][Full Text] [Related]
22. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
23. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.
Stijns RCH; de Graaf EJR; Punt CJA; Nagtegaal ID; Nuyttens JJME; van Meerten E; Tanis PJ; de Hingh IHJT; van der Schelling GP; Acherman Y; Leijtens JWA; Bremers AJA; Beets GL; Hoff C; Verhoef C; Marijnen CAM; de Wilt JHW;
JAMA Surg; 2019 Jan; 154(1):47-54. PubMed ID: 30304338
[TBL] [Abstract][Full Text] [Related]
24. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma.
Abraha I; Aristei C; Palumbo I; Lupattelli M; Trastulli S; Cirocchi R; De Florio R; Valentini V
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD002102. PubMed ID: 30284239
[TBL] [Abstract][Full Text] [Related]
25. Selected stage IV rectal cancer patients managed by the watch-and-wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery?
Custers PA; Hupkens BJP; Grotenhuis BA; Kuhlmann KFD; Breukink SO; Beets GL; Melenhorst J;
Colorectal Dis; 2022 Apr; 24(4):401-410. PubMed ID: 35060263
[TBL] [Abstract][Full Text] [Related]
26. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
[TBL] [Abstract][Full Text] [Related]
27. Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series.
Asoglu O; Bulut A; Aliyev V; Piozzi GN; Guven K; Bakır B; Goksel S
World J Surg Oncol; 2022 Nov; 20(1):358. PubMed ID: 36352416
[TBL] [Abstract][Full Text] [Related]
28. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
29. Treatment Options for Distal Rectal Cancer in the Era of Organ Preservation.
Wang C; Liu X; Wang W; Miao Z; Li X; Liu D; Hu K
Curr Treat Options Oncol; 2024 Apr; 25(4):434-452. PubMed ID: 38517596
[TBL] [Abstract][Full Text] [Related]
30. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
[TBL] [Abstract][Full Text] [Related]
32. Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection - A Matched-Controlled Study.
Hupkens BJP; Martens MH; Stoot JH; Berbee M; Melenhorst J; Beets-Tan RG; Beets GL; Breukink SO
Dis Colon Rectum; 2017 Oct; 60(10):1032-1040. PubMed ID: 28891846
[TBL] [Abstract][Full Text] [Related]
33. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
[TBL] [Abstract][Full Text] [Related]
34. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
[TBL] [Abstract][Full Text] [Related]
35. Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign.
Rupinski M; Szczepkowski M; Malinowska M; Mroz A; Pietrzak L; Wyrwicz L; Rutkowski A; Bujko K
Eur J Surg Oncol; 2016 Feb; 42(2):288-96. PubMed ID: 26506863
[TBL] [Abstract][Full Text] [Related]
36. National Early Rectal Cancer Treatment Revisited.
Stornes T; Wibe A; Nesbakken A; Myklebust TÅ; Endreseth BH
Dis Colon Rectum; 2016 Jul; 59(7):623-9. PubMed ID: 27270514
[TBL] [Abstract][Full Text] [Related]
37. COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer.
Deijen CL; Velthuis S; Tsai A; Mavroveli S; de Lange-de Klerk ES; Sietses C; Tuynman JB; Lacy AM; Hanna GB; Bonjer HJ
Surg Endosc; 2016 Aug; 30(8):3210-5. PubMed ID: 26537907
[TBL] [Abstract][Full Text] [Related]
38. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Perez RO; Habr-Gama A; Lynn PB; São Julião GP; Bianchi R; Proscurshim I; Gama-Rodrigues J
Dis Colon Rectum; 2013 Jan; 56(1):6-13. PubMed ID: 23222274
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer.
Marks JH; Myers EA; Zeger EL; Denittis AS; Gummadi M; Marks GJ
Surg Endosc; 2017 Dec; 31(12):5248-5257. PubMed ID: 28643051
[TBL] [Abstract][Full Text] [Related]
40. Oncological Outcomes and Hospital Costs of the Treatment in Patients With Rectal Cancer: Watch-and-Wait Policy and Standard Surgical Treatment.
Hupkens BJP; Breukink SO; Stoot JHMB; Toebes RE; van der Sande ME; Melenhorst J; Beets GL; Dirksen CD
Dis Colon Rectum; 2020 May; 63(5):598-605. PubMed ID: 32032202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
